The Long Run with Luke Timmerman

John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.

Ethan Weiss, co-founder and CSO of Marea Therapeutics, brings expertise in novel treatment approaches for cardiovascular disease and diabetes, while CEO Josh Lehrer leads the charge in innovative therapies. They discuss a groundbreaking monoclonal antibody targeting ANG-PTL4 and its promising clinical trial outcomes. The duo shares insights on the importance of remnant cholesterol in risk assessment and health management. Their journey from UCSF Moffett Hospital to biotech showcases pivotal moments in collaboration, emphasizing the shift from research to clinical applications.

Peyton Greenside, co-founder and CEO of BigHat Biosciences, is revolutionizing biologic drug discovery using machine learning. She shares her journey from math enthusiast to CEO, emphasizing the vital role mentorship plays for women in STEM. The discussion dives into how AI and innovative techniques are speeding up antibody design, and the challenges of securing investor confidence in a skeptical industry. With a vision for the future, Greenside reveals how successful early projects can spur rapid advancements in therapeutic development.

Kevin Parker, CEO of Cartography Biosciences, reveals insights on discovering new cancer drug targets through innovative multi-omic tools. He shares his journey from a biologist in Pennsylvania to a leader in biotech, highlighting the personal drive behind his research. The discussion covers advancements in single-cell genomics, the challenges of drug discovery, and the potential impacts of targeted therapies on patient care. Parker emphasizes collaboration and strategic partnerships as key to navigating the complexities of cancer treatment innovation.

David Roblin, CEO of Relation Therapeutics, delves into the revolutionary use of multi-omic tools and machine learning in drug discovery. He discusses the power of collaboration within London's biotech scene and shares insights from his journey from clinical medicine to the pharmaceutical industry. Roblin highlights the importance of teamwork, the impact of non-coding DNA on disease understanding, and how AI integration is transforming drug development. His fascinating perspective on interdisciplinary science and partnerships offers a glimpse into the future of biopharma innovation.

Andy Scharenberg, Co-founder and CEO of Umoja Biopharma, is advancing in vivo CAR-T cell therapies to make life-saving treatments more accessible. He talks about the challenges and breakthroughs in CAR T-cell treatments, including the transformative possibilities of gene therapies. Scharenberg reflects on his journey from medicine to molecular innovation and highlights the importance of collaboration in tackling complex immune disorders. He also shares exciting developments aimed at revolutionizing cancer treatment and enhancing patient outcomes.

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.